{"id":"W2568858752","doi":"10.1016/j.jaad.2016.11.043","title":"Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept","year":2017,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":33,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Secukinumab; Medicine; Dermatology Life Quality Index; Etanercept; Placebo; Quality of life (healthcare); Psoriasis Area and Severity Index; Randomized controlled trial; Psoriasis; Clinical trial; Internal medicine; Dermatology; Psoriatic arthritis; Tumor necrosis factor alpha; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003123343,0.0004574328,0.006758424,0.0001822829,0.0004526827,0.00004544184,0.001201388,0.0004416181,0.00006273948],"category_scores_gemma":[0.004940761,0.0002522754,0.001634678,0.0001347499,0.002059563,0.0002648193,0.0002382578,0.001115999,0.0000186599],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006340309,"about_ca_system_score_gemma":0.0002311642,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003819288,"about_ca_topic_score_gemma":0.0000224716,"domain_scores_codex":[0.9881651,0.005566046,0.005094476,0.0004200323,0.0002215774,0.0005327033],"domain_scores_gemma":[0.9748526,0.00537778,0.01880857,0.0006611574,0.0002099152,0.00008999649],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9325288,0.0006976385,0.03985357,0.000008943984,0.01158301,0.0001548805,0.001744342,0.00003672247,0.001631014,0.0002142679,0.001346504,0.01020032],"study_design_scores_gemma":[0.953931,0.0007702693,0.02700376,0.0001551852,0.005331483,0.001705052,0.0009752914,0.00002342373,0.007636292,0.0003381816,0.001743037,0.0003869989],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923952,0.001062714,0.00009071823,0.003666862,0.0009695035,0.001152193,0.0001655758,0.00002457884,0.0004726523],"genre_scores_gemma":[0.9984444,0.0004321225,0.0004195012,0.0003289448,0.000146327,0.00002497559,0.00002229716,0.00003384327,0.0001476313],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02140224,"threshold_uncertainty_score":0.999993,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09313924228473613,"score_gpt":0.3864747613679332,"score_spread":0.293335519083197,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}